Page last updated: 2024-11-06

prednisolone and Hyperlipoproteinemia Type III

prednisolone has been researched along with Hyperlipoproteinemia Type III in 1 studies

Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.

Hyperlipoproteinemia Type III: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
JOOB, S1
KARPATI, P1

Other Studies

1 other study available for prednisolone and Hyperlipoproteinemia Type III

ArticleYear
[ON ESSENTIAL HYPERLIPEMIA].
    Orvosi hetilap, 1964, Volume: 105

    Topics: Adrenocorticotropic Hormone; Alpha-Globulins; Anemia, Hemolytic, Autoimmune; Beta-Globulins; Blood C

1964